Liposomal Cytarabine as Cancer Therapy: From Chemistry to Medicine

Basit Öğe Kaydı
dc.authoridPezzani, Raffaele/0000-0003-3156-2500
dc.authoridMartorell, Miquel/0000-0003-3183-7623
dc.authoridCruz-Martins, Natalia/0000-0002-5934-5201
dc.authoridRedaelli, Marco/0000-0001-9738-9080
dc.authoridKumar, Pradeep/0000-0002-0892-5425
dc.authoridSharifi-Rad, Javad/0000-0002-7301-8151
dc.authoridSalehi, Bahare/0000-0002-6900-9797
dc.contributor.authorSalehi, Bahare
dc.contributor.authorSelamoglu, Zeliha
dc.contributor.authorMileski, Ksenija S.
dc.contributor.authorPezzani, Raffaele
dc.contributor.authorRedaelli, Marco
dc.contributor.authorCho, William C.
dc.contributor.authorKobarfard, Farzad
dc.date.accessioned2024-11-07T13:35:30Z
dc.date.available2024-11-07T13:35:30Z
dc.date.issued2019
dc.departmentNiğde Ömer Halisdemir Üniversitesi
dc.description.abstractCancer is the second leading cause of death worldwide. The main modality to fight against cancer is surgery, radiotherapy, and chemotherapy, and more recently targeted therapy, gene therapy and immunotherapy, which play important roles in treating cancer patients. In the last decades, chemotherapy has been well developed. Nonetheless, administration of the drug is not always successful, as limited drug dosage can reach the tumor cells.. In this context, the possibility to use an encapsulated anti-cancer drug may potentially solve the problem. Liposomal cytarabine is a formulation with pronounced effectiveness in lymphomatous meningitis and reduced cardiotoxicity if compared to liposomal anthracyclines. Thus, the future liposomal cytarabine use could be extended to other diseases given its reduction in cytotoxic side effects compared to the free formulation. This review summarizes the chemistry and biology of liposomal cytarabine, with exploration of its clinical implications.
dc.description.sponsorshipPortuguese Foundation for Science and Technology (FCT-Portugal) [UID/BIM/04293/2013]; NORTE2020-Programa Operacional Regional do Norte [NORTE-01-0145-FEDER-000012]; CONICYT PIA/APOYO CCTE [AFB170007]
dc.description.sponsorshipN. Martins would like to thank the Portuguese Foundation for Science and Technology (FCT-Portugal) for the strategic project ref. UID/BIM/04293/2013 and NORTE2020-Programa Operacional Regional do Norte (NORTE-01-0145-FEDER-000012). M. Martorell would like to thank the support offered by CONICYT PIA/APOYO CCTE AFB170007.
dc.identifier.doi10.3390/biom9120773
dc.identifier.issn2218-273X
dc.identifier.issue12
dc.identifier.pmid31771220
dc.identifier.scopus2-s2.0-85075438624
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.3390/biom9120773
dc.identifier.urihttps://hdl.handle.net/11480/16543
dc.identifier.volume9
dc.identifier.wosWOS:000506636800022
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMdpi
dc.relation.ispartofBiomolecules
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241106
dc.subjectDepoCyt
dc.subjectliposomal cytarabine
dc.subjectliposomal ara-C
dc.subjectliposomal cytosine arabinoside
dc.subjectchemotherapy
dc.subjectcancer therapy
dc.titleLiposomal Cytarabine as Cancer Therapy: From Chemistry to Medicine
dc.typeReview Article

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu